Minoxidil, found in LONITEN Tablets manufactured by Pfizer, is a peripheral vasodilator that is commonly used to treat hypertension and alopecia.

Johnson & Johnson has announced encouraging initial findings from a critical Phase 3 trial with nipocalimab for treating generalized myasthenia gravis, as well as from a Phase 2 investigation in Sjögren's Disease.

CRC, marked by Wnt pathway hyperactivation and DKK1 regulation, is effectively countered by DKN-01, an IgG4 antibody that neutralizes DKK1.

The Stage 2 trial for Technoderma's drug, TDM-105795, reveals positive outcomes for hair regeneration in individuals with pattern baldness.

Nitrofurantoin, an antibiotic medication approved in 1953 by Procter & Gamble, is used to treat uncomplicated lower urinary tract infections.

Sangamo Therapeutics Reveals New Findings from Phase 1/2 STAAR Research for Fabry Disease Indicating Continuous Efficacy and Unique Safety Data.

Phase 2 results of IL-27, PD-(L)1, VEGF blockade using casdozokitug, atezo, and bev in uHCC patients were presented at 2024 ASCO_GI on Jan 18th.

Findings on CSL and Arcturus' sa-mRNA technology suggest extended immunity compared to standard mRNA COVID booster shots.

Hydrocodone bitartrate is a drug commonly used for pain relief, approved first in the United States. The drug works by binding to opioid receptors in the brain, acting as a mu/kappa/delta agonist.

Incyte has declared the establishment of an asset acquisition deal with MorphoSys AG, granting Incyte unique worldwide privileges for the drug tafasitamab.

The latest clinical results of ADG-126 for metastatic MSS CRC treatment were shared at the 2024 ASCO_GI on Jan 20, 2024.

MorphoSys AG has officially declared that it has formed a strategic alliance through a Business Merger Contract with Novartis data42 AG and the principal entity, Novartis AG.